

Haematologica
HAEMATOL/2020/267526
Version 4

Benefit of intermediate-dose cytarabine containing induction in
molecular subgroups of acute myeloid leukemia

Hui Wei, Chunlin Zhou, Dong Lin, Bingcheng Liu, Yan Li, Xingli Zhao,
Shuning Wei, Benfa Gong, Kaiqi Liu, Xiaoyuan Gong, Yuntao Liu,
Guangji Zhang, Jiayuan Chen, Junping Zhang, Jingjing Jin, Shaowei
Qiu, Runxia Gu, Ying Wang, Yingchang Mi, and Jianxiang Wang

Disclosures: None

Contributions: J-X. W. and H. W. contributed to the study design. J-X. W., H. W., and J-Y. C. were involved in analyzing and interpreting the data. J-X. W., and H. W. wrote the report. All authors were involved in the collection and assembly of clinical data. H. W., D. L., C-L. Z., B-C. L., S-W. Q., R-X. G., Y. L., X-L. Z., S-N. W., B-F. G., K-Q. L., X-Y. G., Y-T. L., G-J. Z., J-P. Z., J-J. J., Y. W., and Y-C. M. provided the study materials or patients. All authors reviewed the report and approved the final version.